Recent Posts
- FDA Okays Blood Test for Ovarian Cancer
- Replication At DNA Damage Sites Highlights Fanconi Anemia And Breast Cancer Proteins
- ASCO To Hold Annual Meeting In Chicago For The Next Ten Years: City Seen As Best Choice To Host Meeting That Continues To Grow
- Protein Partnership Leads To Pediatric Tumor Regression
- ASCO Awarded CEO Cancer Gold Standard: Achievement Underscores Organization’s Commitment To The Health And Well-Being Of Its Employees
Random Posts
- ACG: Data Suggest IBD Link to Skin Cancer (CME/CE)
- American Diabetes Association Related To Studies Published In Diabetelogia Suggesting Possible Link Between Insulin Glargine And Cancer
- Consumer Reports Details The Screening Tests That May Be Unnecessary
- Government Of Canada Approves A New Source Of Medical Isotopes
- DNA Test Could Be Key To Targeting Treatments For Head And Neck Cancer
- Hospital Might Explain Cancer Outcome Disparities (CME/CE)
- ASCO: DNA Repair Gene Predicts Chemo Outcome in Lung Cancer
- AUA: Statin Benefits Linked to Prostate Cancer, BPH, ED
- Secondhand Smoke Exposure In Childhood Increases Lung Cancer Risk Later In Life
- InCytu Cancer Vaccine Implant Able To Search Out And Destroy Cancer Tumors
Prescription Cancer Drugs
AstraZeneca Withdraws Its Marketing Authorisation Application For Zactima (vandetinib), Europe
Posted by: admin in Prescription Cancer Drugs on November 06th, 2009
The European Medicines Agency has been formally notified by AstraZeneca of its decision to withdraw its application for a centralised marketing authorisation for the medicine Zactima (vandetinib), 100 mg film-coated tablets.
Zactima was expected to be used in combination with chemotherapy, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received prior anticancer therapy.
The application for the marketing authorisation for Zactima was submitted to the Agency on 30 June 2009. At the time of the withdrawal, it was under review by the Agency’s Committee for Medicinal Products for Human Use (CHMP).
In its official letter, the company stated that the withdrawal of the application was based on the preliminary comments from the Rapporteur and Co-Rapporteur, which indicate that at this point in time the Committee would be unlikely to conclude on a favourable benefit-risk balance for the product in the treatment of NSCLC in combination with chemotherapy.
More information about Zactima and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency’s website after the next CHMP meeting of 16-19 November 2009.
Notes
1. Withdrawal of an application does not prejudice the possibility of a company making a new application at a later stage.
Source
EMEA
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.